Cardiorenal syndrome

Disease5 papers

Humans3

Trial sponsors

Ural State Medical University
1 trialPhase 4109 people
Yale University
1 trialPhase 230 people

Latest

6

Cardiology in ReviewReviewYesterday

Cardiorenal Syndrome Reimagined: From Hemodynamic Failure to a Multisystem Cardio-Renal-Metabolic-Inflammatory Network in the SGLT2 Era

Cardiovascular-kidney-metabolic syndrome

Journal of Personalized MedicineHumans24 Sep

Exploratory Biomarker-Defined Phenotypic Heterogeneity Beyond a Single Physiological Reserve Construct

American Journal of Cardiovascular DrugsReview16 Sep

SGLT2 Inhibitors in Cardiovascular-Kidney-Metabolic Syndrome: Drugs Unifying Heart, Kidney, and Metabolism Pharmacotherapy

SGLT2 inhibitors

The American Journal of the Medical SciencesHumans29 Aug

Associations of biological aging and biological age acceleration with mortality in patients with cardiorenal syndrome: A prospective cohort study

Preprints.orgHumansPreprint27 Aug

Biomarker-Defined Phenotyping Reveals Patient Heterogeneity Not Captured by a Single Physiological Reserve Score

AHA Scientific Sessions 2025 AbstractHumans3 Nov

Glycemic Status Modifies the Prognostic Value of the Cardiometabolic Index for Cardiorenal Outcomes: Evidence From a Population-Based Cohort Study